November 21, 2015 – During the last few days, the American Food and Drug Administration  (FDA) just extended the armamentarium in the fight against multiple myeloma by two new entries, namely Ixazomib (Ninlaro) and Daratumumab (Darzalex). Both drugs are intended to treat …

FDA extends armamentarium to treat multiple myeloma: Ixazomib (Ninlaro) and Daratumumab (Darzalex) approved Read more »